

References

1. Franklin BA, Thompson PD, Al-Zaiti SS, et al. On behalf of the American Heart Association Physical Activity Committee of the Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology, and Stroke Council. Exercise-related acute cardiovascular events and potential deleterious adaptations following long-term exercise. Downloaded from <http://ahajournals.org> on March 3, 2020. Exercise-Related Acute Cardiovascular Events *Circulation* 2020; 141:00-00. doi:10.1161/CIR.0000000000000749
2. Kim JH, Malhotra R, Chiampas G, et al. Cardiac arrest during long-distance running races. *N Engl J Med*. 2012;366(2):130-40. doi:10.1056/NEJMoa1106468.
3. Mathews SC, Narotsky DL, Bernholt DL, et al. Mortality among marathon runners in the United States, 2000-2009. *Am J Sports Med*. 2012;40(7):1495-500. doi:10.1177/0363546512444555.
4. Siegel AJ, Stec JJ, Lipinska I, et al. Effect of marathon running on inflammatory and hemostatic markers. *Am J Cardiol*. 2001;88(8):918-20, A9. doi:10.1016/s0002-9149(01)01909-9.
5. Kratz A, Wood MJ, Siegel AJ, Hiers JR, VanCott EM. Effects of marathon running on platelet activation markers. Direct evidence for in vivo platelet activation. *Am J Clin Pathol* 2006;125:296-300.
6. Albano AJ, Thompson PD, Kapur NK. Acute coronary thrombosis in Boston marathon runners. *N Engl J Med*. 2012;366(2):185-186.
7. Eberhardt N, Noval MG, Kaur R, et al. SARS-CoV-2 infection triggers pro-atherogenic inflammatory response in human coronary vessels. *Nature Cardiovascular Research* 2023;2:899-916.
8. Williams H, Aenold H. The effects of violent and prolonged exercise upon the heart. *Phila Med J*. 189:1233-1235.
9. Siegel AJ. Pheidippides Redux: reducing the risk for acute cardiac events during marathon running. *Am J Med*. 2012;125:630-635.
10. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study; *N Engl J Med*. 1989;321(3):129-35. doi:10.1056/NEJM198907203210301.
11. TIPS-3 investigators. Polypill plus aspirin reduces the incidence of cardiovascular events by 31%: TIPS-3 *Cardiovasc J Afr*. 2021;32(1):32-40.
12. Roubille F, Bouabdallaoui N, Kouz S, et al. Low-Dose Colchicine in Patients with Type 2 Diabetes and Recent Myocardial Infarction in the COLchicine Cardiovascular Outcomes Trial (COLCOT). *Diabetes Care*. 2024. doi:10.2337/dc23-1825.
13. Siegel AJ. Aspirin to reduce the risk for sudden cardiac death in athletes with elevated C-reactive protein levels. *Am J Med*. 2020; doi:10.1016/j.amjmed.2020.04.004
14. Siegel AJ, Noakes TD. Aspirin to prevent sudden cardiac death in athletes with high coronary artery calcium scores. *Am J Med*. 2019;132:138-141.
15. Razavi AC, Uddin SMI, Dardari ZA, et al. Coronary Artery Calcium for Risk Stratification of Sudden Cardiac Death: The Coronary Artery Calcium Consortium. *JACC Cardiovasc Imaging*. 2022;15(7):1259-1270. doi:10.1016/j.jcmg.2022.02.011.
16. Fuchs A, Kuhl JT, Sigvardsen PE, et al. Subclinical Coronary Atherosclerosis and Risk for Myocardial Infarction in a Danish Cohort: A Prospective Observational Cohort Study. *Ann Intern Med*. 2023;176(4):433-442. doi:10.7326/M22-3027.
17. Aengevaeren VL, Mostard A, Bakker EA, et al. Exercise volume versus intensity and the progression of coronary atherosclerosis in middle-aged men and older athletes: findings from the MARC-2 Study. *Circulation*. 2023.
18. De Bosscher R, Dausin C, Claus P, Bogaert J, Dymarkowski S, Goetschalck K, et al. Lifelong endurance exercise and its relation with coronary atherosclerosis. *Eur Heart J*. 2023; <https://doi.org/10.1093/eurheartj/ehad152>.
19. Siegel AJ. Pre-race aspirin for enhanced primary prevention of marathon-related cardiac arrest: confronting Pheidippides' legacy. *Am J Med*. 2023;136(7):613-615.
20. Siegel AJ. Pre-race aspirin to attenuate the risk for marathon-related cardiac arrest: deconstructing the legacy of Pheidippides. *Eur Heart J*. 2023, ehad641. <https://doi.org/10.1093/eurheartj/ehad641>
21. Bhatia HS, Trainor P, Carlisle S, et al. Aspirin and cardiovascular risk in patients with elevated lipoprotein (a): Multi-Ethnic Study of Atherosclerosis. *JAHA*. 2024;13:e033562.